Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aprea TherapeuticsAPRE +1.19%34 EV-to-OCF is 3.22 as of Jul. 30, 2026. GuruFocus rates APRE with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,410 Biotechnology companies, Aprea Therapeutics ranks worse than 79.86% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Aprea Therapeutics's Enterprise Value is $-38.70 Mil.
Aprea Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-12.02 Mil. Therefore, Aprea Therapeutics's EV-to-OCF for today is 3.22.
The historical rank and industry rank for Aprea Therapeutics's EV-to-OCF or its related term are showing as below:
APRE'
s EV-to-OCF Range Over the Past 10 Years
Min: 3.22 Med: 0 Max: 3.22
Current: 3.22
During the past 9 years, the highest EV-to-OCF of Aprea Therapeutics was 3.22. The lowest was 3.22. And the median was .
APRE's EV-to-OCF is ranked worse than 79.86% of 1410
companies
in the Biotechnology industry
Industry Median: -3.2
vs APRE: 3.22
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Aprea Therapeutics's PE Ratio (TTM) for today is calculated as:
Aprea Therapeutics's share price for today is $0.6272.
Aprea Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.540.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Aprea Therapeutics EV-to-OCF Related Terms
Aprea Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Aprea Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Aprea Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aprea Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aprea Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Aprea Therapeutics's EV-to-OCF falls into.
Aprea Therapeutics's current Enterprise Value is $-38.70 Mil.
Aprea Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.02 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aprea Therapeutics (APRE) has a EV-to-OCF of 3.22 as of Jul. 30, 2026. Over the past decade, Aprea Therapeutics' EV-to-OCF has ranged from 3.22 to 3.22. According to the industry distribution chart, Aprea Therapeutics ranks #1126 out of 1410 companies in the Biotechnology industry, placing it in the top 79.9%.
Is Aprea Therapeutics' EV-to-OCF too high?
Aprea Therapeutics' current EV-to-OCF is 3.22. Over the past 10 years, this metric has ranged from a low of 3.22 to a high of 3.22. Based on the distribution chart, Aprea Therapeutics ranks #1126 out of 1410 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aprea Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Aprea Therapeutics' EV-to-OCF compare to SYBX and MTVA?
According to the Biotechnology industry distribution chart, Aprea Therapeutics ranks #1126 out of 1410 companies for EV-to-OCF. This places Aprea Therapeutics in the lower half of its industry. Historically, Aprea Therapeutics' own EV-to-OCF has ranged from 3.22 to 3.22 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Aprea Therapeutics's current EV-to-OCF is 3.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprea Therapeutics stock overvalued right now?
Aprea Therapeutics (APRE) has a current EV-to-OCF of 3.22. The current EV-to-OCF is 3.22. Aprea Therapeutics' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Aprea Therapeutics (APRE), the current EV-to-OCF is 3.22 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
34GF Score
Get the complete analysis for APRE
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APRE has been successfully added to your 
